Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct 2-phenylimidazo[1,2-<i>a</i>]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands.

iScience·2026
Same author

A simple and robust reporter-based framework for deep functional characterization of PPARγ mutants.

Endocrinology·2026
Same author

Data mining historical Chinese medical recipe collections and nuclear receptor profiling identify plant fractions that modulate glucocorticoid receptor activity.

Frontiers in pharmacology·2026
Same author

FEMA GRAS assessment of natural flavor complexes: Vanilla extract, Bitter almond oil, Wintergreen oil and related flavoring ingredients.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2026
Same author

Advanced glycation end products (AGEs) and in vitro and in vivo approaches to study their mechanisms of action and the protective properties of natural compounds.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

FEMA GRAS assessment of natural flavor complexes: Pepper, ginger, coniferous-derived and related flavoring ingredients.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association·2025

Related Experiment Video

Updated: May 14, 2026

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Robust array-based coregulator binding assay predicting ERα-agonist potency and generating binding profiles

Jac M M J G Aarts1, Si Wang, René Houtman

  • 1Business Unit of Toxicology & Bioassays, RIKILT - Institute of Food Safety, Wageningen University and Research Centre , Akkermaalsbos 2, Wageningen, The Netherlands.

Chemical Research in Toxicology
|February 7, 2013
PubMed
Summary

This study validates an in vitro assay for endocrine disruptor screening. The assay accurately identifies estrogen receptor activity and chemical structural similarities, offering a reliable alternative to animal testing for chemical safety.

More Related Videos

Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Related Experiment Videos

Last Updated: May 14, 2026

Monitoring GPCR-&#946;-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Parallel Interrogation of &#946;-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Area of Science:

  • Toxicology
  • Biochemistry
  • Chemical Safety Testing

Background:

  • Endocrine-disrupting chemicals pose risks, necessitating reliable safety testing.
  • In vitro alternatives to animal testing are crucial for evaluating estrogen receptor (ER) signaling interference.
  • An ERα-coregulator peptide binding assay shows promise for replacing traditional uterotrophic assays.

Purpose of the Study:

  • To determine the reproducibility and robustness of an in vitro ERα-coregulator binding assay.
  • To assess the assay's ability to predict estrogenicity and classify ERα endocrine disruptors.
  • To evaluate the correlation between binding affinity, potency, and structural characteristics of tested compounds.

Main Methods:

  • Validated an in vitro assay profiling ligand-induced binding of ERα to coregulator peptides.
  • Tested 14 model compounds recommended for laboratory proficiency testing.
  • Assessed reproducibility using median coefficient of variation and correlation coefficients (R²).
  • Compared ERα-coregulator binding potency with ER binding affinity and transactivation assay results.
  • Utilized hierarchical clustering to analyze structural similarities among compounds.

Main Results:

  • The ERα-coregulator binding assay demonstrated high reproducibility (median CV = 5.0%) and excellent correlation (R² = 0.993) in duplicate measurements.
  • The assay correctly predicted estrogenicity for 13 out of 14 tested compounds.
  • Excellent correlations were observed between ERα-coregulator binding potency, ER binding affinity (R² = 0.96), and transactivation potency (R² = 0.94).
  • Hierarchical clustering successfully grouped structurally related compounds and distinguished between different steroid A-ring structures.

Conclusions:

  • The ERα-coregulator binding assay is a reproducible and robust method for identifying ERα agonists and antagonists.
  • The assay accurately predicts estrogenicity and reflects structural similarities of ERα agonists.
  • This in vitro assay holds significant potential for high-fidelity identification and classification of ERα endocrine disruptors, serving as a valuable alternative to animal testing.